CASE REPORT

Idiopathic stuttering priapism treated with salbutamol orally: a case report F. Migliorini, A. B. Porcaro, R. Baldassarre & W. Artibani Department of Urology, University Hospital, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

Keywords Baclofen—cyproterone acetate—recurrent ischaemic priapism—salbutamol Correspondence Filippo Migliorini, MD, Department of Urology, University Hospital, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale Ludovido Scuro n. 10, CAP 37134, Verona, Italy. Tel.: +39 045 812 3313; Fax: +39 045 812 3471; E-mail: [email protected] Accepted: March 24, 2015

Summary Recurrent ischaemic priapism also known as stuttering priapism is an uncommon form of ischaemic priapism, and its treatment is not yet clearly defined. If left untreated, it may evolve into classic form of acute ischaemic priapism and lead to erectile dysfunction due to fibrosis of corpora cavernosa. Several drugs have been proposed with variable results and only supported with level three or four of evidence. Hormonal therapy such as cyproterone acetate, oestrogen, bicalutamide or Lh-Rh agonist are often effective but can cause side effects such as hypogonadal state and infertility. Other medical options are 5-alphareductase and phosphodiesterase-5 inhibitors, ketoconazole, baclofen, digoxin, gabapentin and beta-2-agonist terbutaline. We report the first case of stuttering priapism treated with beta-2-agonist salbutamol.

doi: 10.1111/and.12438

Introduction

Case report

Traditionally, priapism has been classified into three main categories: ischaemic, nonischaemic and recurrent or stuttering (Levey et al., 2014). Recurrent ischaemic priapism (RIP) is an uncommon condition whereby patients develop prolonged, self-limiting, episodic, unwanted, painful, sleeprelated erections (SREs) that typically last less than 3–4 h (Muneer et al., 2008). If these episodes are not treated, it may evolve into a classic ischaemic priapism and eventually leads to irreversible corporal fibrosis with erectile dysfunction (Morrison & Burnett, 2012). The goal of the management of RIP is the prevention of future episodes (Hoeh & Levine, 2014). Current medical options include anti-androgens (Dahm et al., 2002), LH-RH agonist (Levine & Guss, 1993), 5-alpha-reductase inhibitors (Rachid-Filho et al., 2009), oestrogen (Serjeant et al., 1985), ketoconazole (KTZ) (Hoeh & Levine, 2014), phosphodiesterase-5 inhibitors (PDE5i) (Burnett et al., 2006), digoxin (Gupta et al., 1998), gabapentin (Perimenis et al., 2004), baclofen (Rourke et al., 2002) and terbutaline (Muneer et al., 2008; Kheirandish et al., 2011; Levey et al., 2012). Herein we report a case of RIP successfully treated with oral salbutamol. According to the best of our knowledge, this is the first case reported in the English literature which has been treated with such medication.

A 22-year-old Caucasian man was referred to our outpatient andrology clinic for prolonged morning erections lasting from 2 to 4 h. The symptom began 3 months before, after an episode of acute ischaemic priapism treated with cavernosal blood aspiration and intracavernosal etilefrine. At that time, diazepam 10 mg tid was started. The patient had no medical comorbidities, in particular no sickle-cell disease or any other haematological pathology and no prior history of genital or pelvic trauma. The penis colour Doppler ultrasound did not show arteriovenous fistula and sexual hormonal levels, and the central nervous system MRI was normal. Diazepam was stopped, and cyproterone acetate 100 mg daily was given with good control of the symptomatology. After 4 months, cyproterone was gradually reduced to 25 mg daily within a month. Two weeks after the reduction of cyproterone to 25 mg per day, there were two ischaemic priapic events in 1 week which required cavernosal puncture and blood aspiration. Cyproterone acetate 100 mg daily was resumed. Because of the patient’s young age, a seminal analysis was performed and showed azoospermia. Baclofen 30 mg daily was started, and cyproterone was gradually reduced until stopped within a month. Two weeks after cyproterone suspension, episodes of ischaemic

238

© 2015 Blackwell Verlag GmbH Andrologia 2016, 48, 238–240

F. Migliorini et al.

priapism started again. Baclofen was stopped, and the patient was taught self-intracavernosal etilefrine injection which was necessary two times per week. For this reason, we prescribed salbutamol orally 2 mg bid and after a week 4 mg before bed and 2 mg early in the morning. Two weeks later, no more episodes of priapism occurred and no side effects were reported. After 3 months of therapy, the patient is well with morning erections lasting less than one hour and spermatozoa analysis got back to normal according to WHO 1999. Discussion Stuttering priapism shares its aetiologies with ischaemic priapism, and these include haematological dyscrasias (mainly sickle-cell disease), neurological disorders and idiopathic (Kheirandish et al., 2011). Patients with RIP typically present with short-lived (

Idiopathic stuttering priapism treated with salbutamol orally: a case report.

Recurrent ischaemic priapism also known as stuttering priapism is an uncommon form of ischaemic priapism, and its treatment is not yet clearly defined...
54KB Sizes 2 Downloads 18 Views

Recommend Documents


Stuttering priapism associated with topiramate.
Priapism, or prolonged penile erection in the absence of sexual stimulation, may be a medical emergency. Many medications including antianxiety, antidepressants and antipsychotics have been implicated. This paper presents a case of priapism associate

Priapism associated with iloperidone: a case report.
Priapism is a known side effect of antipsychotics. The causal mechanism seems to be mediated through α1-adrenergic receptor blockade which many antipsychotics are known to possess. We present the first detailed case of iloperidone-induced priapism in

Semi-rigid penile prosthesis as a salvage management of idiopathic ischemic stuttering priapism.
Priapism is the persistent erection resulting from dysfunction of the mechanisms that regulate penile swelling, stiffness, and sagging. It is a full or partial erection that persists for a period more than 4 hours beyond sexual stimulation and/or org

Homosexuality treated adventitiously in a stuttering therapy program: a case report presenting a heterophobic orientation.
Australian and New Zealand Journal of Psychiatry (1976) 10: 185 HOMOSEXUALITY TREATED ADVENTITIOUSLY IN A STUTTERING THERAPY PROGRAM: A CASE REPORT P

Leech Therapy for Treating Priapism: Case Report.
Priapism is well-defined by persistent, painful penile erection which happens without sexual stimulation. Currently, the hirudotherapy is practiced to treat venous congestion and subsequent compartment syndrome. Here we will report a case of a male w

CNV amplitude as a neural correlate for stuttering frequency: A case report of acquired stuttering.
A neural hallmark of developmental stuttering is abnormal articulatory programming. One of the neurophysiological substrates of articulatory preparation is the contingent negative variation (CNV). Unfortunately, CNV tasks are rarely performed in pers

A case report of priapism caused by ziprasidon.
Priapism is defined as having prolonged (more than 6 h), and usually painful penile erection that occurs without a sexual desire or arousal. Only a very few priapism cases caused by ziprasidone are reported in the literature. In this case report we a

Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid: A case report.
Plasma exchange is the principal treatment for acquired thrombotic thrombocytopenic purpura (TTP) but is invasive and may have adverse effects. Reports of immunoglobulin therapy for acquired TTP without plasma exchange are rare.

Priapism Followed by Discontinuation of Methadone: A rare Case Report.
Priapism is defined by persistent, painful penile erection which occurs without sexual stimulation. Methadone is used as an analgesic and is also used in detoxification and maintenance protocol for opioid dependence treatment. Here we will report a c